January 30, 2018 / 2:17 AM / 8 months ago

BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film

Jan 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd

* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes)

* Study CTH-300 met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants

Source text in Japanese:goo.gl/sE7Qks

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below